10 completed. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 10 |
| Phase 1 | 2 | Completed 2 |
Follow Metastatic Prostate Carcinoma: new trials by email Literature Review of Metastatic Prostate Carcinoma trials Research Report on Metastatic Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone Computed Tomography, Fluciclovine F18, Positron Emission Tomography - Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone | Phase 2 | Completed | University of Utah | 17 | 2018-10-02 | 2024-11-29 |
| 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Completed | Jonsson Comprehensive Cancer Center | 937 | 2018-04-02 | 2021-09-30 |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer ESK981 - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 13 | 2018-03-08 | 2023-07-14 |
| Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer CT (Computed Tomography), Gallium Ga 68-DOTATATE, Positron Emission Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Completed | Emory University | 17 | 2018-02-22 | 2025-07-17 |
| Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway Carboplatin, Docetaxel, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | University of Washington | 14 | 2016-01-26 | 2022-11-17 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer Pembrolizumab, pTVG-HP Plasmid DNA Vaccine - Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone | Phase 1 / Phase 2 | Completed | University of Wisconsin, Madison | 66 | 2015-07-01 | 2023-08-01 |
| Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Laboratory Biomarker Analysis, Sipuleucel-T, Tasquinimod - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 2 | 2015-01-01 | 2023-04-27 |
| CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 54 | 2013-09-10 | 2019-07-09 |
| Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Abiraterone Acetate, Laboratory Biomarker Analysis, Pharmacological Study - Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Completed | University of Washington | 32 | 2012-12-01 | 2021-05-14 |
| Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 170 | 2012-07-11 | 2021-07-30 |
Prostatic Neoplasms (10) · Lymphadenopathy (1)
Genital Diseases (10) · Genital Diseases, Male (10) · Genital Neoplasms, Male (10) · Male Urogenital Diseases (10) · Neoplasms (10) · Neoplasms by Site (10) · Prostatic Diseases (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Hemic and Lymphatic Diseases (1) · Lymphatic Diseases (1)
Magnetic Resonance Spectroscopy (3) · Carboplatin (2) · 68Ga-DKFZ-PSMA-11 (1) · Abiraterone Acetate (1) · Docetaxel (1) · Ga(III)-DOTATOC (1) · Immunoglobulin G (1) · Prednisone (1) · XRP6258 (1) · cabazitaxel (1) · deltacortene (1) · fluciclovine F-18 (1) · gallium 68 PSMA-11 (1) · gallium Ga 68 dotatate (1) · pembrolizumab (1)
University of Washington (2) · Barbara Ann Karmanos Cancer Institute (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Roswell Park Cancer Institute (1) · University of Utah (1) · University of Wisconsin, Madison (1)
United States (10)
Douglas G McNeel, MD PhD (1) · Elisabeth I. Heath (1) · Heather H. Cheng (1) · Jeffrey Yap, PhD (1) · Jeremie Calais (1) · Lawrence Fong (1) · Martin A. Cheever (1) · Mehmet Asim Bilen, MD (1) · Paul Corn (1) · Robert Montgomery (1) · Saby George (1)
PMID 29876010, PMID 30700328, PMID 31515154, PMID 33602654, PMID 35277461, PMID 39227508, PMID 41378786, PMID 41698328
P30CA015704 (3), P50CA097186 (2), P30CA016672 (1), P30CA022453 (1), U01CA154967 (1)